Los trastornos inducidos por sustancias y la conducciónel ejemplo del Interferón

  1. Hervás Zuriaga, Alejandra
  2. Ferrero Berlanga, Javier
  3. Civera Mollá, Cristina
  4. Tortosa Gil, Francisco Manuel
Journal:
Revista española de drogodependencias

ISSN: 0213-7615

Year of publication: 2011

Issue Title: Uso y abuso de drogas: risgos de accidentes en la conducción

Issue: 3

Pages: 303-315

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Revista española de drogodependencias

Abstract

In order to condense the latest developments in research into the interaction of psychoactive drugs in the skills involved in driving, a search in PubMed and PsycINFO was made, using keywords benzodiazepines, antidepressants, neuroleptics AND drive, driving and drivers. In the paper all articles published from January 2006 until October 2010 were reviewed.

Bibliographic References

  • Ademmer, K., Beutel, M., Bretzel, R., Jaeger, C. y Reimer, C. (2001). Suicidal Ideation With IFN- alpha and Ribavirin in a Patient With Hepatitis C. Psychosomatics. Vol. 42(4), p. 365-367.
  • Aguilar, J. (2009). Viral dynamics and prediction of response to treatment with pegylated Interferon and Ribavirin in patients with chronic hepatitis C. Revista española de enfermedades digestivas. Vol. 101(10), p. 665-670.
  • Agra, S. (2007). Interferón y Depresión. Anales de Psiquiatría. Vol. 23(5), p.256- 266.
  • Amodio, P., De Toni, E., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Zanone, S., Chemello, L., Gatta, A. y Perinic, G. (2005). Mood, cognition and EEG changes during Interferon alpha treatment for chronic hepatitis C. Journal of Aff ective Disorders. Vol. 84(1), p.93-98.
  • APA (American Psychiatric Association) First MB, Frances A, Pincus HA. (2000). DSMIV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Ed. Elsevier- Masson.
  • Asnis, G., De La Garza, R., Miller, A., y Raison, C. (2004). Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. Journal of Clinical Psychiatry.Vol. 65(4), p.581-582.
  • Blank, V. y Roguin, L. (2003). El interferón Alfa: una proteína de uso terapéutico. Ciencia Hoy. Vol. 12(72), p. 20-31.
  • Bourgeois, J., Rossaro, L. y Canning, R. (2005). Depression as Co-Pilot: clinical implications of hepatitis C and Interferon/Ribavirin treatment. Psychiatric Times. Vol. 22(5), p. 77- 81.
  • Carta, M., Hardoy, M., Garofalo, A., Pisano, E., Nonnoi, V., Intilla, G., Serra, G., Balestrieri, C., Chessa, L., Cauli, C., Eliana, M. y Farci, P. (2007). Association of chronic hepatitis C with major depressive disorders: irrespective of Interferon-alpha therapy. Clinical Practice and Epidemiology in Mental Health. Vol. 3(22), p. 1-4.
  • Córdoba, J., Reyes, J. y Esteban, J.I. (2003). Labeling may be an important cause of reduced quality of life in chronic hepatitis C. The American Journal of Gastroenterology. Vol. 98(1), p.226-227.
  • Dan, A., Martin, L., Crone, C., Ong, J., Farmer, D., Wise, T., Robbins, S. y Younossi, Z. (2006). Depression, anemia and health related quality of life in chronic hepatitis C. Journal of Hepatology. Vol. 44(3), p.491-498.
  • Del Río, M., Álvarez, F. y González-Luque, J. (2001). Guía de prescripción farmacológica y seguridad vial. Dirección General de Tráfico.
  • Dieperink, E., Willenbring, M. y Ho, S. (2000). Neuropsychiatric symptoms associated with hepatitis C and Interferon alpha: a review. American Journal of Psychiatry. Vol. 157(6), p. 867-876.
  • Dieperink, E., Ho, S., Tetrick, L., Thuras, P., Dua, K. y Willenbring, M. (2004). Suicidal ideation during Interferon-α2b and ribavirin treatment of patients with chronic hepatitis C. General Hospital Psychiatry. Vol. 26(3), p.237-240.
  • Dieperink, E., Leskela, J., Dieperink, M., Evans, B., Thuras, P. y Ho, S. (2008). The eff ect of pegylated Interferon-2b and Ribavirin on posttraumatic stress disorder symptoms. Psychosomatics. Vol. 49(3), p.225-229.
  • Dwight, M., Kowdley, K., Russo, J., Ciechanowski, P., Larson, A. y Katon, W. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychosomatic Research. Vol.49(5), p.311-317.
  • Ferrero, J., Hervás, A., Civera, C. y Tortosa, F. (2011 en prensa). Un estudio piloto sobre el efecto diferencial de la fatiga por conducción en personas mayores. Universitas Psychologica. Vol. 10(3).
  • Fonda, S., Wallace, R. y Herzog, A. (2001). Changes in driving patterns and worsening depressive symptoms among older adults. The Journals of Gerontology, Series B: Psychological Sciences. Vol. 56(6), p.343–351.
  • Gallardo, M., Baños R., Belloch, A. y Ruipérez, M. (1999). Attentional biases and vulnerability to depression. The Spanish Journal of Psychology. Vol. 2(1), p.11-19.
  • Golden, J., O’Dwyer, A. y MConroy, R. (2005). Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. General Hospital Psychiatry. Vol.27(6), p.431– 438.
  • Grassi, L., Mondardini, D., Pavanati, M., Sighinolfi , L., Serra, A. y Ghinelli, F. (2001). Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus and HIV/ HCV-seronegative injecting drug users. Journal of Aff ective Disorders. Vol. 64(2-3), p. 195-202.
  • Hervás, A., Ferrero, J. y Civera, C. (2011). La fatiga en la conducción. Un estudio empírico. Securitas Vialis. Vol. 8(3), 33-48.
  • Hilton, M., Staddon, Z., Sheridanb, J. y Whiteford, H. (2009). The impact of mental health symptoms on heavy goods vehicle drivers’ performance. Accident Analysis & Prevention. Vol. 41(3), p. 453-461.
  • Hosoda, S., Takimura, H., Shibayama, M., Kanamura, H., Ikeda, K. y Kumada H. (2000). Psychiatric symptoms related to Interferón therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry and clinical Neurosciences. Vol. 54(5), p.565-572.
  • Hunt, C., Dominitz, J., Philips, B., Waters, B., Blasi, U. y Williams, D. (1997). Eff ect of Interferon-alfa treatment of chronic hepatitis C on health-related quality of life. Digestive Diseases and Science. Vol. 42(12), p. 2482-2486.
  • Keefe, B. (2009). Interferon-induced depression in hepatitis C: An update. Current psychiatry reports. Vol. 9(3), p. 255-261.
  • Kraus, M., Schäfer A., Csef, H., Scheurlen, M. y Faller, H. (2000). Emotional state, coping styles, and Somatic variables in patients with chronic hepatitis C. Psychosomatics: Journal of Consultation Liaison Psychiatry. Vol. 41(5), p. 377-384.
  • Majer, M., Welberg, L., Capuron, L., Pagnoni, G., Raison, C. y Miller, A. (2008). IFN-alphainduced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain, Behavior, and Immunity. Vol. 22(6), p.870–880.
  • Monterde, H. (1986). La batería psicológica informatizada Driver-Test. Valencia: Servicio de Publicaciones de la Facultad de Psicología.
  • Musselman, D., Lawson, D., Gumnick, J., Manatunga, A., Penna, S., Goodkin, R., Greiner, K., Nemeroff , C. y Miller, A. (2001). Paroxetine for the prevention of depression induced by high-dose Interferon alfa. The New England Journal of Medicine. Vol. 344(13), p. 961-966.
  • Perry, W., Hilsabeck, R. y Hassanein, T. (2008). Cognitive dysfunction in chronic hepatitis C: a review. Digestive Diseases and Sciences. Vol. 53(2), p. 307–321.
  • Pugnetti, L., Colombo, A., Cazzullo, C., Leccardi, G., Sicuro, F. y Scarone, S. (1982). Daytime sleep patterns of primary depressives: A morning nap study. Psychiatry Research. Vol. 7(3), p.287-298.
  • Raison, C., Borisov, A., Broadwell, S., Capuron, L., Woolwine, B., Jacobson, I., Nemeroff , C. y Miller, A. (2005). Depression during pegylated Interferon alpha plus Ribavirin therapy: prevalence and prediction. The Journal of Clinical Psychiatry. Vol. 66(1), p. 41-48.
  • Rodríguez, M., Rodríguez, E., Vázquez, F., Rodríguez, J. y San-Miguel, A. (2001). Medicamentos y conducción de vehículos. Off arm:Farmacia y Sociedad. Vol. 20(1), p.92-98.
  • Rubinsztein, J. y Lawton, C. (1995). Depression and driving in the elderly. International Journal of Geriatric Psychiatry. Vol. 10(1), p.15–17.
  • Saunders, J. (2008). Neuropsychiatric Symptoms of Hepatitis C. Issues in Mental Health Nursing. Vol. 29(3), p.209-220.
  • Schaefer, M., Schwaiger, M., Garkisch, A., Pich, M., Hinzpeter, A., Uebelhack, R., Heinz, A., Van Boemmelb, F. y Berg, T. (2005). Prevention of Interferon-alpha associated depression in psychiatric risk patientswith chronic hepatitis C. Journal of Hepatology. Vol. 42(6), p.793-798.
  • Tortosa, F., Civera, C. y Pastor, J. (2001). Una historia para un perfi l profesional. El psicólogo experto en seguridad vial. Revista de Historia de la Psicología. Vol. 22(3-4), p. 543-559.
  • Wilson, M., Castillo, E., Batey, A., Sapyta, J. y Aronson, S. (2010). Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. The International Journal of Psychiatry in Medicine. Vol. 40(2), p. 199-215.
  • Wood, J. y Troutbeck, R. (1992). Eff ect of restriction of the binocular visual fi eld on driving performance. Ophthalmic and Physiological Optics. Vol. 12(3), p.291-298.
  • Wood, J. y Troutbeck, R. (1994). Eff ect of visual impairment on driving. Human Factors. Vol. 36(3), p.476-487.
  • Zigmond, A. y Snaith, R. (1983). The hospital and anxiety and depression scale. Acta Psychatrica Scandinava. Vol. 67, p.361-370.
Data source: Dialnet